Northwestern University
AIDS Clinical Trial Group (ACTG)

Contact: Baiba Berzins (312) 695-5012


A5353: Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV Patients 

A5353 is a single-arm study for people who have HIV and have never taken HIV medications. Participants will receive dual therapy with dolutegravir (Tivicay) plus lamivudine (Epivir) for 52 weeks.

Who can join this study? 

  • HIV-1 infected women and men at least 18 years of age
  • Have never taken HIV medications
  • HIV level (viral load) between 1,000 and 500,000 copies/mL
  • No active hepatitis B infection

A5332: Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) 

REPRIEVE is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months. The trial is testing the effect of statin therapy on preventing heart disease and death in HIV-infected persons on HIV medications who do not meet guidelines for starting statins.

Who can join this study? 

  • HIV-1 infected women and men between the ages of 40-75
  • On anti-HIV medications for at least 6 months
  • CD4 count greater than 100
  • No history of cardiovascular disease, such as heart attack, stroke, etc
  • No history of cancer in last 3 years
  • Not currently using a statin drug

University of Chicago
Chicago Center for HIV Elimination (CCHE)

Contact: Andrew Richardson or
Billy Davis (773) 675-9390


Transmission Reduction Intervention Project (TRIP)

TRIP recruits individuals and members of their social networks who may be at heightened risk of HIV infection due to acute or recent  infection  (within previous 9 months)  in their community. The goal of the study is to prevent the transmission of HIV and other sexually transmitted diseases. Participants will be interviewed and tested for HIV and Syphilis on two different dates, six months apart. The interview includes questions about access to healthcare, people the participant knows, and venues the participant uses to meet sex partners.

Who can join this study? 

  • HIV-1 infected women and men at least 18 years of age
  • And who have acute infection or documented seroconversion in the previous 9 months